- Home
- MRVI vs TERN Comparison
MRVI vs TERN Comparison
Compare MRVI & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVI
- TERN
- Stock Information
- Founded
- MRVI 2014
- TERN 2017
- Country
- MRVI United States
- TERN United States
- Employees
- MRVI N/A
- TERN 59
- Industry
- MRVI Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- MRVI Health Care
- TERN Health Care
- Exchange
- MRVI Nasdaq
- TERN Nasdaq
- Market Cap
- MRVI 312.4M
- TERN 262.9M
- IPO Year
- MRVI 2020
- TERN 2021
- Fundamental
- Price
- MRVI $2.22
- TERN $3.50
- Analyst Decision
- MRVI Hold
- TERN Buy
- Analyst Count
- MRVI 10
- TERN 5
- Target Price
- MRVI $6.84
- TERN $15.63
- AVG Volume (30 Days)
- MRVI 1.9M
- TERN 695.0K
- Earning Date
- MRVI 05-12-2025
- TERN 05-08-2025
- Dividend Yield
- MRVI N/A
- TERN N/A
- EPS Growth
- MRVI N/A
- TERN N/A
- EPS
- MRVI N/A
- TERN N/A
- Revenue
- MRVI $241,856,000.00
- TERN N/A
- Revenue This Year
- MRVI N/A
- TERN N/A
- Revenue Next Year
- MRVI $10.73
- TERN N/A
- P/E Ratio
- MRVI N/A
- TERN N/A
- Revenue Growth
- MRVI N/A
- TERN N/A
- 52 Week Low
- MRVI $1.67
- TERN $1.87
- 52 Week High
- MRVI $10.03
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- MRVI 52.01
- TERN 66.38
- Support Level
- MRVI $2.20
- TERN $3.01
- Resistance Level
- MRVI $2.41
- TERN $3.17
- Average True Range (ATR)
- MRVI 0.15
- TERN 0.20
- MACD
- MRVI 0.01
- TERN 0.04
- Stochastic Oscillator
- MRVI 58.06
- TERN 88.89
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.